Drug Topics
JUNE 30, 2024
High-volume pharmacy fulfillment requires addressing unique factors like demand profiles, prescription throughput, and specialized processing to design a solution to address your specific needs and growth goals. This article covers steps for designing fulfillment solutions, including assessing demand, choosing appropriate automation technologies, and addressing conveyance, packaging, and sortation needs.
STAT
JUNE 30, 2024
The National Academies of Sciences, Engineering, and Medicine recently released a congressionally mandated report on how to make amyotrophic lateral sclerosis — a brutal, always fatal condition — a “livable” disease in the next 10 years. Essentially, the committee was tasked with delivering a plan for a moonshot. As a health care innovation expert and someone living with ALS, I have to say that the report barely gets off the ground.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 30, 2024
In case you missed it, this week we had news about mosquito-associated health risks, the link between cannabis and COVID-19, user experience in continuous glucose monitoring, and more.
STAT
JUNE 30, 2024
A few years ago, the Centers for Medicare and Medicaid Services launched a big experiment. The agency wanted to see if financial incentives and penalties would improve care for people with end-stage kidney disease. So far, it hasn’t worked, a new study finds. The End-Stage Renal Disease Treatment Choices (ETC) model is a historic effort, both because it’s the largest such experiment in the history of American health care and because, unlike previous CMS Innovation Center pilot prog
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JUNE 30, 2024
Catch up on important continuous glucose monitoring (CGM) news from the month of June.
Fierce Healthcare
JUNE 30, 2024
As Walmart shutters its primary care clinics, the retail giant inked a deal to sell its MeMD telehealth business to healthcare technology startup Fabric. | The deal will significantly expand Fabric's reach in the employer market as MeMD provides virtual care services to 30,000 employers and 5 million employees.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Med Ed 101
JUNE 30, 2024
With this med review, I’m simply looking at a medication list to help formulate ideas to investigate. I’ll focus heavily on my concern for using an NSAID in this patient. NSAID and Heart Failure Concerns There are a few issues of note with the cardiac/heart failure medication regimen. I always have the prescribing cascade in […] The post NSAID Problems – Polypharmacy Case Study appeared first on Med Ed 101.
pharmaphorum
JUNE 30, 2024
After FDA rejection last year, ARS Pharma closes on EU approval for intranasal epinephrine product for anaphylaxis
BioPharm
JUNE 30, 2024
Webinar Date/Time: Wed, Jul 24, 2024 12:00 PM EDT
The FDA Law Blog
JUNE 30, 2024
RAPS Convergence 2024 is set to host a must-attend session on CDRH’s Total Product Life Cycle Advisory Program (TAP), promising attendees an exclusive insight into a pioneering initiative aimed at improving the medical device commercialization landscape. Session Details: A Path to Faster Breakthrough Device Commercialization – CDRH’s Total Product Life Cycle Advisory Program (TAP) Thursday, September 19, 2024, 4:30 PM – 5:30 PM Session Leader: Adrienne Lenz, RAC – Principal Medical Device Regula
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
BioPharm
JUNE 30, 2024
In this asset, you will discover how the Gibco Efficient-Pro system can revolutionize your mAb manufacturing workflow. It provides insights into optimizing CHO cell productivity, enhancing product titers and protein quality, streamlining process efficiency, and leveraging a reliable supply network.
BioPharm
JUNE 30, 2024
Discover how the Gibco™ Efficient-Pro™ system boosts productivity, enhances cell viability, and ensures superior product quality with minimal impurities. Packed with detailed fed-batch study results, this guide offers actionable insights and practical tips to optimize your bioproduction processes, ensuring you achieve higher yields and consistent, high-quality outcomes.
BioPharm
JUNE 30, 2024
Learn about how Efficient-Pro Medium and Feeds elevate productivity in CHO-K1, CHO-S, and DG44 cells for bioproduction in this comprehensive content piece.
BioPharm
JUNE 30, 2024
This asset outlines the comprehensive support and guidance offered by the FAS team for optimizing monoclonal antibody (mAb) manufacturing processes using the Efficient-Pro medium and feeds. Readers will learn about the tailored assistance provided at every stage, including troubleshooting, recommendations, ongoing support, site visits, and prioritization of confidentiality.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
247 
Let's personalize your content